{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-057861","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.450144+00:00","generated_at":"2026-06-27T03:40:46.700739+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Revolution Medicines Q4 net loss $52.7M, FY2021 net loss $187.1M; RAS pipeline advances","bullets":["Cash, cash equivalents and marketable securities $577.1M at Dec 31, 2021 vs $440.7M at Dec 31, 2020.","Total revenue $9.5M Q4 2021 vs $8.8M Q4 2020; FY2021 $29.4M vs $43.0M FY2020 (incl. $8.5M non-cash adjustment).","Net loss $52.7M Q4 2021 vs $34.2M Q4 2020; FY2021 $187.1M vs $108.2M FY2020.","Full year 2022 GAAP net loss guidance $260M-$290M; stock-based comp $35M-$40M.","RMC-4630+sotorasib Phase 2 first patient dosed; IND plans: RMC-6236 & RMC-6291 H1 2022, RMC-9805 H1 2023, RMC-8839 H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-057861","json":"https://secwatch.observer/filing/0001193125-22-057861.json","markdown":"https://secwatch.observer/filing/0001193125-22-057861.md","text":"https://secwatch.observer/filing/0001193125-22-057861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522057861/0001193125-22-057861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522057861/d214686d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:40:46.700739+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}